688363 华熙生物
交易中 08-18 13:02:13
资讯
新帖
简况
华熙生物自历史高点跌88% 某券商历史高位月2度喊买
中金财经 · 08-14
华熙生物自历史高点跌88% 某券商历史高位月2度喊买
每周股票复盘:华熙生物(688363)JUVELOOK获NMPA批准10月上市
证券之星 · 08-02
每周股票复盘:华熙生物(688363)JUVELOOK获NMPA批准10月上市
华熙生物获得发明专利授权:“一种具有紫外线防御作用的组合物及其应用”
证券之星 · 08-01
华熙生物获得发明专利授权:“一种具有紫外线防御作用的组合物及其应用”
华熙生物获得发明专利授权:“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”
证券之星 · 08-01
华熙生物获得发明专利授权:“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”
华熙生物:7月30日进行路演,方正证券、东方证券等多家机构参与
证券之星 · 07-30
华熙生物:7月30日进行路演,方正证券、东方证券等多家机构参与
华熙生物获得发明专利授权:“一种降低氨基酸表面活性剂的临界胶束浓度的方法”
证券之星 · 07-29
华熙生物获得发明专利授权:“一种降低氨基酸表面活性剂的临界胶束浓度的方法”
华熙生物获得发明专利授权:“一种菌体冻干保护剂及其用途”
证券之星 · 07-29
华熙生物获得发明专利授权:“一种菌体冻干保护剂及其用途”
华熙生物涨5.26%,开源证券二个月前给出“买入”评级
证券之星 · 07-22
华熙生物涨5.26%,开源证券二个月前给出“买入”评级
华熙生物涨6.08%,开源证券二个月前给出“买入”评级
证券之星 · 07-15
华熙生物涨6.08%,开源证券二个月前给出“买入”评级
每周股票复盘:华熙生物(688363)股东户数减少6.08%
证券之星 · 07-12
每周股票复盘:华熙生物(688363)股东户数减少6.08%
华熙生物“分子抗氧贴”专利获批,实现16小时长效抗氧化
金融界 · 07-08
华熙生物“分子抗氧贴”专利获批,实现16小时长效抗氧化
股市必读:华熙生物(688363)股东户数2.92万户,较上期减少6.08%
证券之星 · 07-08
股市必读:华熙生物(688363)股东户数2.92万户,较上期减少6.08%
华熙生物:截至2026年06月30日,公司股东人数为29,241户
证券之星 · 07-07
华熙生物:截至2026年06月30日,公司股东人数为29,241户
华熙生物(688363)披露2025年年度权益分派实施公告,7月6日股价下跌2.79%
证券之星 · 07-06
华熙生物(688363)披露2025年年度权益分派实施公告,7月6日股价下跌2.79%
华熙生物赵燕:关于我的江湖传言比较多,不是真实的
新浪财经 · 07-03
华熙生物赵燕:关于我的江湖传言比较多,不是真实的
华熙生物赵燕:人工智能提早了对未病的干预,人可能还会逆生长
新浪财经 · 07-03
华熙生物赵燕:人工智能提早了对未病的干预,人可能还会逆生长
华熙生物赵燕:从理论上讲人是可以永生的,只不过被七情六欲影响了
睿见Economy · 07-03
华熙生物赵燕:从理论上讲人是可以永生的,只不过被七情六欲影响了
破发股华熙生物跌2.67% 2019年上市募23.69亿
中金财经 · 06-24
破发股华熙生物跌2.67% 2019年上市募23.69亿
华熙生物(688363)披露2025年年度股东会决议公告,6月16日股价下跌0.25%
证券之星 · 06-16
华熙生物(688363)披露2025年年度股东会决议公告,6月16日股价下跌0.25%
华熙生物涨7.20%,开源证券一个月前给出“买入”评级
证券之星 · 06-12
华熙生物涨7.20%,开源证券一个月前给出“买入”评级
加载更多
公司概况
公司名称:
华熙生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2019-11-06
主营业务:
华熙生物科技股份有限公司的主营业务是研发、生产和销售透明质酸等生物活性物质原料产品及生物医用材料终端产品。公司的主要产品是原料产品、医疗终端产品、皮肤科学创新转化业务。公司坚持科技创新驱动发展,科技创新能力多次获得国家及各级政府认可。公司先后被认定为国家企业技术中心、国家药监局化妆品原料质量控制重点实验室(联合申报)、山东省生物活性物合成生物学重点实验室、海南省再生医学技术与材料转化重点实验室、天津市生物合成与过程工程重点实验室、糖类智造及功能应用北京市重点实验室等科研平台,并参与共建国家合成生物技术创新中心及国家生物制造产业创新中心。凭借在技术创新和产业引领方面的突出表现,公司获得国家制造业单项冠军示范企业、国家知识产权优势企业、山东省科技进步一等奖、山东省省长质量奖、中国商业联合会特等奖等多项国家级、省级荣誉。
发行价格:
47.79
{"stockData":{"symbol":"688363","market":"SH","secType":"STK","nameCN":"华熙生物","latestPrice":36.37,"timestamp":1787029333000,"preClose":36.97,"halted":0,"volume":1791943,"delay":0,"changeRate":-0.0162,"floatShares":482000000,"shares":482000000,"eps":0.5291,"marketStatus":"交易中","change":-0.6,"latestTime":"08-18 13:02:13","open":36.8,"high":37.07,"low":36.36,"amount":65676600,"amplitude":0.0192,"askPrice":36.37,"askSize":28,"bidPrice":36.36,"bidSize":66,"shortable":0,"etf":0,"ttmEps":0.5291,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787036400000},"marketStatusCode":2,"adr":0,"adjPreClose":36.97,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787016600000,1787023800000],[1787029200000,1787036400000]],"highLimit":40.67,"lowLimit":33.27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":481678242,"isCdr":false,"pbRate":2.5,"roa":"--","peRate":68.739369,"roe":"0.91%","epsLYR":0.61,"committee":0.032538,"marketValue":17519000000,"turnoverRate":0.0037,"status":1,"floatMarketCap":17519000000},"requestUrl":"/m/hq/s/688363","defaultTab":"news","newsList":[{"id":"2659411273","title":"华熙生物自历史高点跌88% 某券商历史高位月2度喊买","url":"https://stock-news.laohu8.com/highlight/detail?id=2659411273","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659411273?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:08","pubTimestamp":1786698481,"startTime":"0","endTime":"0","summary":"中国经济网北京8月14日讯 华熙生物(688363.SH)今日收报37.45元,跌幅2.90%。\r\n\r\n 2021年7月5日,华熙生物股价创下上市以来的高点314.99元。经复权,华熙生物股价较历史高点跌幅达87.81%。\r\n\r\n 国金证券股份有限公司研究员袁维2021年7月5日发布研报《华熙生物 (688363)公司点评:营收端超预期增长 功能性护肤品持续放量》称,维持“买入”评级。\r\n\r\n 国金证券股份有限公司研究员袁维2021年7月20日发布研报《华熙生物 (688363)深度报告:四轮驱动战略建立透明质酸全产业链布局》称,维持“买入”评级。\r\n\r\n (责任编辑:徐自立)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260814/32335331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688363","BK0229","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656578316","title":"每周股票复盘:华熙生物(688363)JUVELOOK获NMPA批准10月上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2656578316","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656578316?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:42","pubTimestamp":1785606135,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,华熙生物报收于40.03元,较上周的36.33元上涨10.18%。答:2026年7月28日,公司代理的韩国VIM GLOBL聚乳酸面部填充剂JUVELOOK正式获得国家药品监督管理局批准上市。答:JUVELOOK于2014年在韩国上市,目前已进入全球60多个国家和地区,累计销量超过300万瓶,具备良好的国际市场验证基础。答:JUVELOOK获批后,国内上市准备工作已启动,产品预计于2026年10月正式上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656396235","title":"华熙生物获得发明专利授权:“一种具有紫外线防御作用的组合物及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2656396235","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656396235?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:38","pubTimestamp":1785526712,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“一种具有紫外线防御作用的组合物及其应用”,专利申请号为CN202410382572.4,授权日为2026年7月31日。今年以来华熙生物新获得专利授权38个,较去年同期减少了5%。通过天眼查大数据分析,华熙生物科技股份有限公司共对外投资了34家企业,参与招投标项目505次;财产线索方面有商标信息5505条,专利信息939条,著作权信息114条;此外企业还拥有行政许可93个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100003624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656396420","title":"华熙生物获得发明专利授权:“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2656396420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656396420?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:38","pubTimestamp":1785526703,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“N-乙酰葡萄糖胺-2-差向异构酶突变体和N-乙酰神经氨酸裂合酶突变体及其应用”,专利申请号为CN202411996519.X,授权日为2026年7月31日。专利摘要:本申请提供一种N乙酰葡萄糖胺2差向异构酶突变体和N乙酰神经氨酸裂合酶突变体及其应用。今年以来华熙生物新获得专利授权38个,较去年同期减少了5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100003594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655014876","title":"华熙生物:7月30日进行路演,方正证券、东方证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2655014876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655014876?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:01","pubTimestamp":1785409281,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年7月30日华熙生物发布公告称公司于2026年7月30日进行路演,方正证券、东方证券、国泰海通证券、申万宏源、云富投资集团有限公司参与。本次产品代理将进一步完善公司医美产品布局,但未来销售情况将受到行业政策、市场竞争、需求变化等因素影响,对公司业绩影响具有不确定性。该股最近90天内共有7家机构给出评级,买入评级5家,增持评级2家;过去90天内机构目标均价为60.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000032424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1147","BK0028","BK0122","600958","601901","03958","BK0183","BK0276","BK1564","688363","BK0188","BK0229","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882737","title":"华熙生物获得发明专利授权:“一种降低氨基酸表面活性剂的临界胶束浓度的方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882737","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655882737?lang=zh_cn&edition=full","pubTime":"2026-07-29 03:34","pubTimestamp":1785267292,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“一种降低氨基酸表面活性剂的临界胶束浓度的方法”,专利申请号为CN202310330806.6,授权日为2026年7月28日。今年以来华熙生物新获得专利授权35个,较去年同期减少了12.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900003720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655267882","title":"华熙生物获得发明专利授权:“一种菌体冻干保护剂及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2655267882","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655267882?lang=zh_cn&edition=full","pubTime":"2026-07-29 03:32","pubTimestamp":1785267164,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华熙生物新获得一项发明专利授权,专利名为“一种菌体冻干保护剂及其用途”,专利申请号为CN202211633922.7,授权日为2026年7月28日。其中,所述菌体冻干保护剂包括透明质酸或其盐和鼠李糖。今年以来华熙生物新获得专利授权35个,较去年同期减少了12.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900003184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753139","title":"华熙生物涨5.26%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653753139?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:45","pubTimestamp":1784709928,"startTime":"0","endTime":"0","summary":"今日华熙生物涨5.26%,收盘报38.8元。2026年4月24日,开源证券研究员黄泽鹏,李昕恬发布了对华熙生物的研报《公司信息更新报告:主动变革利润高增,合成生物学管线突破可期》,该研报对华熙生物给出“买入”评级。公司是玻尿酸龙头,全产业链协同发力,战略调整已卓有成效,期待后续盈利能力持续优化,估值合理,维持“买入”评级。华熙生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651453992","title":"华熙生物涨6.08%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651453992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651453992?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:22","pubTimestamp":1784103740,"startTime":"0","endTime":"0","summary":"今日华熙生物涨6.08%,收盘报36.45元。2026年4月24日,开源证券研究员黄泽鹏,李昕恬发布了对华熙生物的研报《公司信息更新报告:主动变革利润高增,合成生物学管线突破可期》,该研报对华熙生物给出“买入”评级。公司是玻尿酸龙头,全产业链协同发力,战略调整已卓有成效,期待后续盈利能力持续优化,估值合理,维持“买入”评级。华熙生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154130","title":"每周股票复盘:华熙生物(688363)股东户数减少6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650154130?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:38","pubTimestamp":1783795091,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,华熙生物报收于35.71元,较上周的37.32元下跌4.31%。本周,华熙生物7月6日盘中最高价报37.5元。股本股东变化股东户数变动截至2026年6月30日,公司股东户数为2.92万户,较5月8日减少1892.0户,减幅为6.08%。北京市通商律师事务所关于华熙生物科技股份有限公司差异化分红事项之专项法律意见书华熙生物因实施股份回购,回购专用证券账户中的3,315,538股不参与2025年度利润分配,导致总股本与实际参与分配股份数存在差异,构成差异化分红。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649975951","title":"华熙生物“分子抗氧贴”专利获批,实现16小时长效抗氧化","url":"https://stock-news.laohu8.com/highlight/detail?id=2649975951","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649975951?lang=zh_cn&edition=full","pubTime":"2026-07-08 10:02","pubTimestamp":1783476160,"startTime":"0","endTime":"0","summary":"近日,华熙生物创新研究院自主研发的“分子抗氧贴”化妆品组合物技术正式获得国家发明专利授权。抗氧化“短效失效”,消费者与品牌双重难题随着功效护肤需求持续升级,抗氧化已成为护肤核心刚需赛道。阿魏酸、麦角硫因保护率稳定超 40%,16小时仍可维持有效抗氧化浓度,可覆盖日间全时段防护需求。","market":"fut","thumbnail":"http://imgcloud.jrjimg.cn/2026/07/08/0481ce2c82c60277c470c0e795c6230f.jpeg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/07/08/0481ce2c82c60277c470c0e795c6230f.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/07/08100257736567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934787","title":"股市必读:华熙生物(688363)股东户数2.92万户,较上期减少6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934787","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649934787?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:23","pubTimestamp":1783448594,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘,华熙生物报收于34.72元,下跌4.3%,换手率0.65%,成交量3.13万手,成交额1.1亿元。股本股东变化:截至2026年6月30日,股东户数为2.92万户,较5月8日减少6.08%;户均持股由1.59万股增至1.65万股。谢谢董秘: 尊敬的投资者,您好,截至2026年06月30日,公司股东人数为29,241户,感谢您的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800001268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649600834","title":"华熙生物:截至2026年06月30日,公司股东人数为29,241户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649600834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649600834?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:51","pubTimestamp":1783410694,"startTime":"0","endTime":"0","summary":"证券之星消息,华熙生物(688363)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2026年6月30日公司的股东总数是多少?谢谢华熙生物回复:尊敬的投资者,您好,截至2026年06月30日,公司股东人数为29,241户,感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700023216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649627038","title":"华熙生物(688363)披露2025年年度权益分派实施公告,7月6日股价下跌2.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649627038","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649627038?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:38","pubTimestamp":1783348698,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘,华熙生物报收于36.28元,较前一交易日下跌2.79%,最新总市值为174.75亿元。该股当日开盘37.5元,最高37.5元,最低36.12元,成交额达1.5亿元,换手率为0.85%。近日,华熙生物科技股份有限公司发布《2025年年度权益分派实施公告》:每股现金红利0.19元(含税),股权登记日为2026年7月10日,除权(息)日为2026年7月13日,现金红利发放日为2026年7月13日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600037749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661352","title":"华熙生物赵燕:关于我的江湖传言比较多,不是真实的","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661352","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648661352?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:09","pubTimestamp":1783087740,"startTime":"0","endTime":"0","summary":" 7月3日消息,亚布力中国企业家论坛第十二届创新年会7月3日-4日在上海召开。华熙生物创始人兼董事长赵燕在大健康论坛表示,“关于我的这种江湖传言也比较多,大家可能都听了一个七七八八,那都是网上自媒体说的,不是真实的。” 谈到创业,赵燕表示,其实创业要问自己做企业的初心是什么,这一点非常重要,初心即是巅峰,出发点其实就是终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-07-03/doc-inifpyyn5554857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648666245","title":"华熙生物赵燕:人工智能提早了对未病的干预,人可能还会逆生长","url":"https://stock-news.laohu8.com/highlight/detail?id=2648666245","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648666245?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:53","pubTimestamp":1783083180,"startTime":"0","endTime":"0","summary":" 7月3日消息,亚布力中国企业家论坛第十二届创新年会7月3日-4日在上海召开。华熙生物创始人兼董事长赵燕在大健康论坛表示,人工智能的发展,尤其这三年,其实拓展了人类对于生命的认知边界。 赵燕表示,原来有病才去医院,同样一个病,不同的人是一个治疗方法,但现在人工智能的发展,就会针对不同的人做到一人一策,现在已经往这个方向走。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-07-03/doc-inifpuss2383559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["QLD","688363","PSQ","NAPR","07261","QDEC","QID","161631","QMAR","QSWN","BK0229","07522","TQQY","NEWZ","TARK","ARTY","BK4593","07266","OGIG","09086","TQQQ","NOCT","FWD","03034","AIFD","AIBU","QQQ","MVPS","02834","LCLG","AGIX","NJUL","07568","NBDS","CPNQ","GPIQ","QQQX","CHAT","QQQM","NJAN","QTOC","KOMP","QQA","03455","03086","SQQQ","BK0239","GK","09834"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648666435","title":"华熙生物赵燕:从理论上讲人是可以永生的,只不过被七情六欲影响了","url":"https://stock-news.laohu8.com/highlight/detail?id=2648666435","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648666435?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:45","pubTimestamp":1783082700,"startTime":"0","endTime":"0","summary":" 7月3日-4日,2026亚布力论坛创新年会在上海市举行。本次创新年会的主题是“创新驱动智启未来——十五五蓝图与企业机遇”。 华熙生物创始人兼董事长赵燕大健康论坛上表示,人工智能的发展拓展了对于生命的认知边界,对于生命、寿命的理解,边界在一点一点的打破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-07-03/doc-inifpusq5598216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893185","title":"破发股华熙生物跌2.67% 2019年上市募23.69亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893185","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645893185?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:14","pubTimestamp":1782288842,"startTime":"0","endTime":"0","summary":"中国经济网北京6月24日讯 华熙生物 今日收报35.73元,跌幅2.67%。该股目前处于破发状态。 2019年11月6日,华熙生物在上交所科创板上市,发行价格为47.79元/股,募集资金总额为23.69亿元,扣除发行费用后,募集资金净额为22.49亿元。华熙生物的发行费用合计为11,964.01万元,其中保荐及承销费等为9,666.00万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260624/32288344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643632557","title":"华熙生物(688363)披露2025年年度股东会决议公告,6月16日股价下跌0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643632557","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643632557?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:33","pubTimestamp":1781620395,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,华熙生物报收于36.2元,较前一交易日下跌0.25%,最新总市值为174.37亿元。该股当日开盘36.11元,最高36.8元,最低35.66元,成交额达1.22亿元,换手率为0.7%。华熙生物科技股份有限公司于2026年6月16日在山东省济南市高新区召开2025年年度股东会,会议由董事长赵燕主持,采用现场与网络投票相结合的方式进行。出席会议的股东及代理人共297人,代表表决权股份319,025,076股,占公司总表决权股份的66.6910%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642265970","title":"华熙生物涨7.20%,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642265970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642265970?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:29","pubTimestamp":1781252962,"startTime":"0","endTime":"0","summary":"今日华熙生物涨7.20%,收盘报37.2元。2026年4月24日,开源证券研究员黄泽鹏,李昕恬发布了对华熙生物的研报《公司信息更新报告:主动变革利润高增,合成生物学管线突破可期》,该研报对华熙生物给出“买入”评级。公司是玻尿酸龙头,全产业链协同发力,战略调整已卓有成效,期待后续盈利能力持续优化,估值合理,维持“买入”评级。华熙生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787029337028,"stockEarnings":[{"period":"1week","weight":-0.0501},{"period":"1month","weight":0.0216},{"period":"3month","weight":-0.0715},{"period":"6month","weight":-0.2134},{"period":"1year","weight":-0.3027},{"period":"ytd","weight":-0.1491}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.058},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.0244},{"period":"1year","weight":0.0773},{"period":"ytd","weight":0.0035}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华熙生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29241人(较上一季度减少3.77%)","perCapita":"16472股","listingDate":"2019-11-06","address":"山东省济南市历下区高新技术开发区天辰大街678号","registeredCapital":"48167万元","survey":" 华熙生物科技股份有限公司的主营业务是研发、生产和销售透明质酸等生物活性物质原料产品及生物医用材料终端产品。公司的主要产品是原料产品、医疗终端产品、皮肤科学创新转化业务。公司坚持科技创新驱动发展,科技创新能力多次获得国家及各级政府认可。公司先后被认定为国家企业技术中心、国家药监局化妆品原料质量控制重点实验室(联合申报)、山东省生物活性物合成生物学重点实验室、海南省再生医学技术与材料转化重点实验室、天津市生物合成与过程工程重点实验室、糖类智造及功能应用北京市重点实验室等科研平台,并参与共建国家合成生物技术创新中心及国家生物制造产业创新中心。凭借在技术创新和产业引领方面的突出表现,公司获得国家制造业单项冠军示范企业、国家知识产权优势企业、山东省科技进步一等奖、山东省省长质量奖、中国商业联合会特等奖等多项国家级、省级荣誉。","listedPrice":47.79},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华熙生物,688363,华熙生物股票,华熙生物股票老虎,华熙生物股票老虎国际,华熙生物行情,华熙生物股票行情,华熙生物股价,华熙生物股市,华熙生物股票价格,华熙生物股票交易,华熙生物股票购买,华熙生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}